EA202090316A1 - Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения - Google Patents
Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее полученияInfo
- Publication number
- EA202090316A1 EA202090316A1 EA202090316A EA202090316A EA202090316A1 EA 202090316 A1 EA202090316 A1 EA 202090316A1 EA 202090316 A EA202090316 A EA 202090316A EA 202090316 A EA202090316 A EA 202090316A EA 202090316 A1 EA202090316 A1 EA 202090316A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antigen
- immunogenic composition
- increased
- hepatitis
- improved
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 230000003247 decreasing effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 9
- 102000036639 antigens Human genes 0.000 abstract 9
- 108091007433 antigens Proteins 0.000 abstract 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 3
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 2
- 208000002672 hepatitis B Diseases 0.000 abstract 2
- 229960000814 tetanus toxoid Drugs 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000606768 Haemophilus influenzae Species 0.000 abstract 1
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 208000000474 Poliomyelitis Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229940001442 combination vaccine Drugs 0.000 abstract 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721025513 | 2017-07-18 | ||
| PCT/IB2018/055180 WO2019016654A1 (en) | 2017-07-18 | 2018-07-13 | IMMUNOGENIC COMPOSITION WITH IMPROVED STABILITY, ENHANCED IMMUNOGENICITY, AND LESS REACTOGENICITY, AND PREPARATION METHOD THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090316A1 true EA202090316A1 (ru) | 2020-12-08 |
Family
ID=63556364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090316A EA202090316A1 (ru) | 2017-07-18 | 2018-07-13 | Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11179453B2 (https=) |
| EP (1) | EP3655024A1 (https=) |
| JP (1) | JP7404226B2 (https=) |
| KR (1) | KR102657910B1 (https=) |
| CN (1) | CN111032078A (https=) |
| AU (1) | AU2018302767B2 (https=) |
| BR (1) | BR112020000999A2 (https=) |
| CA (1) | CA3070039A1 (https=) |
| CO (1) | CO2020001765A2 (https=) |
| EA (1) | EA202090316A1 (https=) |
| GE (2) | GEAP202115276A (https=) |
| JO (1) | JOP20180069B1 (https=) |
| MX (1) | MX2020000441A (https=) |
| PE (1) | PE20201443A1 (https=) |
| PH (1) | PH12020500133A1 (https=) |
| SG (1) | SG11202000224SA (https=) |
| TW (1) | TWI786153B (https=) |
| UA (1) | UA128204C2 (https=) |
| UY (1) | UY37811A (https=) |
| WO (1) | WO2019016654A1 (https=) |
| ZA (1) | ZA202000889B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110072A1 (es) * | 2005-06-27 | 2011-02-04 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| US9119804B2 (en) | 2006-03-10 | 2015-09-01 | Institut Pasteur De Lille | Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| SG175803A1 (en) | 2009-04-28 | 2011-12-29 | Pasteur Institut | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
| SG11202003333WA (en) * | 2017-10-18 | 2020-05-28 | Pasteur Institut | Bordetella strains expressing serotype 3 fimbriae |
| EA202190778A1 (ru) * | 2018-10-12 | 2021-08-05 | Серум Инститьют Оф Индия Прайват Лтд | Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения |
| WO2020165920A1 (en) * | 2019-02-12 | 2020-08-20 | Biological E Limited | Multivalent vaccine composition |
| CN112138155B (zh) | 2019-06-28 | 2022-04-12 | 怡道生物科技(苏州)有限公司 | 一种复合佐剂系统及制备该佐剂的方法 |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
| EP3988288A1 (en) | 2020-10-23 | 2022-04-27 | Carl Zeiss Vision International GmbH | Method of manufacturing a spectacle lens |
| EP3988289A1 (en) | 2020-10-23 | 2022-04-27 | Carl Zeiss Vision International GmbH | Method of manufacturing a spectacle lens |
| EP3988290A1 (en) | 2020-10-23 | 2022-04-27 | Carl Zeiss Vision International GmbH | Method for manufacturing a spectacle lens |
| KR102815484B1 (ko) * | 2020-11-30 | 2025-06-04 | 주식회사 엘지화학 | 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법 |
| KR102861088B1 (ko) * | 2021-04-20 | 2025-09-17 | 케이엠 바이올로직스 가부시키가이샤 | 6종 혼합 액상 백신 조성물 |
| JP2026509511A (ja) * | 2023-03-16 | 2026-03-19 | アフィニバックス、インコーポレイテッド | 免疫原性組成物 |
| CN119799602A (zh) * | 2025-03-17 | 2025-04-11 | 艾美坚持生物制药有限公司 | 一种破伤风梭状芽胞杆菌发酵培养基及培养方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG48365A1 (en) | 1992-05-23 | 1998-04-17 | Smithkline Beecham Biolog | Combined vaccines comprising hepatitis b surface antigen and other antigens |
| PL184872B1 (pl) | 1995-06-23 | 2003-01-31 | Smithkline Beecham Biolog | Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie |
| BR9714980A (pt) | 1997-09-15 | 2001-11-06 | Pasteur Merieux Msd | Vacinas multivalentes |
| GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| EP1004314A1 (fr) | 1998-11-26 | 2000-05-31 | Pasteur Merieux MSD | Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée |
| UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
| GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| GB0616226D0 (en) * | 2006-08-15 | 2006-09-27 | Novartis Ag | Processes |
| JP5814507B2 (ja) | 2006-09-07 | 2015-11-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| PE20100366A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
| PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
| EP2661277A2 (en) | 2011-01-05 | 2013-11-13 | Bharat Biotech International Limited | A combination heptavalent vaccine |
| MX2016001695A (es) * | 2013-08-05 | 2016-05-02 | Glaxosmithkline Biolog Sa | Composiciones inmunogenas de combinacion. |
| TN2018000063A1 (en) * | 2015-09-16 | 2019-07-08 | Lg Chemical Ltd | Combination vaccine composition for multiple-dosage. |
-
2018
- 2018-07-13 CN CN201880048015.1A patent/CN111032078A/zh active Pending
- 2018-07-13 JP JP2020502265A patent/JP7404226B2/ja active Active
- 2018-07-13 PE PE2020000084A patent/PE20201443A1/es unknown
- 2018-07-13 BR BR112020000999-7A patent/BR112020000999A2/pt unknown
- 2018-07-13 EA EA202090316A patent/EA202090316A1/ru unknown
- 2018-07-13 MX MX2020000441A patent/MX2020000441A/es unknown
- 2018-07-13 US US16/631,965 patent/US11179453B2/en active Active
- 2018-07-13 KR KR1020207004735A patent/KR102657910B1/ko active Active
- 2018-07-13 SG SG11202000224SA patent/SG11202000224SA/en unknown
- 2018-07-13 UA UAA202000861A patent/UA128204C2/uk unknown
- 2018-07-13 CA CA3070039A patent/CA3070039A1/en active Pending
- 2018-07-13 AU AU2018302767A patent/AU2018302767B2/en active Active
- 2018-07-13 EP EP18768937.7A patent/EP3655024A1/en active Pending
- 2018-07-13 WO PCT/IB2018/055180 patent/WO2019016654A1/en not_active Ceased
- 2018-07-13 GE GEAP202115276A patent/GEAP202115276A/en unknown
- 2018-07-13 GE GEAP201815276A patent/GEP20227386B/en unknown
- 2018-07-17 UY UY0001037811A patent/UY37811A/es not_active Application Discontinuation
- 2018-07-17 TW TW107124600A patent/TWI786153B/zh active
- 2018-07-17 JO JOP/2018/0069A patent/JOP20180069B1/ar active
-
2020
- 2020-01-17 PH PH12020500133A patent/PH12020500133A1/en unknown
- 2020-02-11 ZA ZA2020/00889A patent/ZA202000889B/en unknown
- 2020-02-17 CO CONC2020/0001765A patent/CO2020001765A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018302767A1 (en) | 2020-03-05 |
| JOP20180069B1 (ar) | 2022-09-15 |
| CA3070039A1 (en) | 2019-01-24 |
| TW201919690A (zh) | 2019-06-01 |
| WO2019016654A1 (en) | 2019-01-24 |
| US20200206331A1 (en) | 2020-07-02 |
| GEP20227386B (en) | 2022-06-10 |
| EP3655024A1 (en) | 2020-05-27 |
| SG11202000224SA (en) | 2020-02-27 |
| AU2018302767B2 (en) | 2025-04-10 |
| ZA202000889B (en) | 2021-06-30 |
| CO2020001765A2 (es) | 2020-05-29 |
| CN111032078A (zh) | 2020-04-17 |
| MX2020000441A (es) | 2020-08-17 |
| PE20201443A1 (es) | 2020-12-10 |
| KR102657910B1 (ko) | 2024-04-18 |
| TWI786153B (zh) | 2022-12-11 |
| BR112020000999A2 (pt) | 2020-07-14 |
| KR20200042470A (ko) | 2020-04-23 |
| GEAP202115276A (en) | 2021-12-27 |
| JOP20180069A1 (ar) | 2019-01-18 |
| JP2020527571A (ja) | 2020-09-10 |
| US11179453B2 (en) | 2021-11-23 |
| UA128204C2 (uk) | 2024-05-08 |
| JP7404226B2 (ja) | 2023-12-25 |
| PH12020500133A1 (en) | 2021-02-08 |
| UY37811A (es) | 2019-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090316A1 (ru) | Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения | |
| RU2013136397A (ru) | Комбинированная семивалентная вакцина | |
| RU2011120308A (ru) | Комбинированная вакцина с ацеллюлярным коклюшем | |
| IL164812A0 (en) | Packaged virus-like particles for use as adjuvants: method of preparation and use | |
| WO2017096341A3 (en) | Adenovirus-vectored multivalent vaccine | |
| NZ592977A (en) | IgE CH3 PEPTIDE VACCINE | |
| DK1951299T3 (da) | Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere | |
| RU2006136212A (ru) | КОМБИНИРОВАННЫЕ ВАКЦИНЫ С НИЗКОЙ ДОЗОЙ КОНЬЮГАТА Hib | |
| BRPI0520330B8 (pt) | adjuvante a base de ácido polinosínico-policitidílico | |
| JP2015531389A5 (https=) | ||
| RU2015106745A (ru) | Иммуногенные композиции | |
| RU2504398C2 (ru) | Комбинированная вакцина с цельноклеточным коклюшем | |
| RU2015111987A (ru) | Несшитые бесклеточные коклюшные антигены для применения в комбинированных вакцинах | |
| MX2019001780A (es) | Composicion de vacuna multivalente novedosa. | |
| RU2016141621A (ru) | Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин | |
| AR117191A1 (es) | Composiciones inmunogénicas | |
| AR101256A1 (es) | Composición vacunal que comprende ipv y ciclodextrinas | |
| JP2022511511A5 (https=) | ||
| HUP0104125A2 (hu) | Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal | |
| MY208608A (en) | Liquid sextuple vaccine composition | |
| RU2010106557A (ru) | Метод получения гипериммунной сыворотки против вируса парагриппа-3 крупного рогатого скота | |
| NZ751127B2 (en) | Multivalent vaccine composition | |
| XU | Immunogenicity evaluation of prototype and variant inactivated SARS-CoV-2 vaccines in rats | |
| REN et al. | Immunogenicity and safety of the acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenza type b conjugate vaccine (DTaP-IPV/Hib combined vaccine): a meta-analysis | |
| AR118407A1 (es) | Composición de vacuna multivalente |